Did DYN Therapeutics Inc take over the mining companies shell?
Recent DYN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:35:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:09:33 PM
- Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) • GlobeNewswire Inc. • 03/08/2026 10:01:00 PM
- Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) • GlobeNewswire Inc. • 03/08/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:10:20 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/06/2026 05:57:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/02/2026 12:52:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 12:35:27 PM
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 03/02/2026 12:30:00 PM
- Dyne Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference • GlobeNewswire Inc. • 02/22/2026 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:09:42 PM
- Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 • GlobeNewswire Inc. • 01/20/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 12:35:31 PM
- Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/07/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 12:35:24 PM
- Dyne Therapeutics Appoints Vikram Karnani to Board of Directors • GlobeNewswire Inc. • 12/23/2025 12:30:00 PM
- Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares • GlobeNewswire Inc. • 12/11/2025 09:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/10/2025 09:31:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2025 09:22:33 PM
- Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/10/2025 02:42:38 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/08/2025 09:19:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2025 09:07:54 PM
- Dyne Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 12/08/2025 09:02:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
